As psychedelic therapies inch closer to potential approvals, it’s prudent to begin thinking about what strings may be attached to such approvals. In the U.S., the Food and Drug Administration (FDA) often mandates the provision of Risk Evaluation and Mitigation Strategies (REMS) programs alongside (or, after) the approval of a potentially dangerous therapeutic, in an attempt to ensure the benefits…


Previous articleLevitee Labs Announces DTC Eligibility Approval
Next articleMINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy